Optimum Misoprostol Dose Prior to Office Hysteroscopy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

132 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-06-30

Study Completion Date

2013-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Misoprostol is an effective agent for cervical priming before office hysteroscopy, vaginal route is the best, optimum dose not yet known.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Misoprostol for Cervical Priming Before Office Hysteroscopy

NCT03276000

Misoprostol Allergy

UNKNOWN PHASE2/PHASE3

Impact of Misoprostol on Blood Loss In Myomectomy Operations

NCT02061657

Leiomyoma

COMPLETED PHASE3

Misoprostol Prior to Office Hysteroscopy in Patients With no Risk Factors for Experiencing Unacceptable Pain

NCT02318225

Pain

UNKNOWN PHASE2

Dose Comparison of Misoprostol for Cervix Ripening Before Operative Hysteroscopy.

NCT04152317

Cervix; Open

COMPLETED PHASE3

Optimal Timing of Misoprostol Administration Prior to Office Hysteroscopy

NCT02316301

Pain

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators will compare between 2 different doses of vaginal misoprostol, group (1) 200 ug, group (2) 400 ug, 3hours prior to office hysteroscopy , Infertile patient, patients with abnormal bleeding and patient with recurrent abortion Outcome measure: pain score, easiness of the procedure, procedure time, complications

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infertility Abnormal Uterine and Vaginal Bleeding, Unspecified Recurrent Abortion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Misoprostol vaginally, 200 ug

200 ug misoprostol in the posterior vaginal fornix

Group Type ACTIVE_COMPARATOR

Misoprostol

Intervention Type DRUG

200 ug

Misoprostol vaginally, 400ug

Misoprostol in the posterior vaginal fornix

Group Type ACTIVE_COMPARATOR

Misoprostol

Intervention Type DRUG

Misoprostol vaginally, 400 ug

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Misoprostol

200 ug

Intervention Type DRUG

Misoprostol

Misoprostol vaginally, 400 ug

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female patient pre- or postmenopausal undergo office hysteroscopy.
* Age: from 20 to 60.
* BMI between 18 and 30.

Exclusion Criteria

* PID or
* Heavy uterine bleeding
* Cervical malignancy.
* Symptoms suggestive of endometriosis .
* Any cervical abnormality such as pinhole cervix that would obviate passage of a catheter through the cervix.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes